Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK - Wikidata - awgldk - TriplyDB

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

http://www.wikidata.org/entity/Q27640998

about

Studies ofToxoplasma gondiiandPlasmodium falciparumenoyl acyl carrier protein reductase and implications for the development of antiparasitic agents Type I and type II fatty acid biosynthesis in Eimeria tenella: enoyl reductase activity and structure Crystal structure of enoyl-acyl carrier protein reductase (FabK) fromStreptococcus pneumoniaereveals the binding mode of an inhibitor Design and Synthesis of Aryl Ether Inhibitors of theBacillus AnthracisEnoyl-ACP Reductase Slow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis : Residence Time and in Vivo Activity Identification and Development of Novel Inhibitors of Toxoplasma gondii Enoyl Reductase Determination of the Crystal Structure and Active Residues of FabV, the Enoyl-ACP Reductase from Xanthomonas oryzae Structural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of Francisella tularensis Enoyl Reductase (FabI) Inhibitors Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis Dendralenes Branch Out: Cross-Conjugated Oligoenes Allow the Rapid Generation of Molecular Complexity Discovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction.Enzymes of type II fatty acid synthesis and apicoplast differentiation and division in Eimeria tenella.Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI)Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.Methyl 3-(1H-indol-3-yl)propano-ate 'FAS't inhibition of malaria.Anti-Toxoplasma Activity of 2-(Naphthalene-2-γlthiol)-1H Indole.Inhibiting bacterial fatty acid synthesis.The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection.Fungal naphtho-γ-pyrones: Potent antibiotics for drug-resistant microbial pathogens.Direct Effect of Two Naphthalene-Sulfonyl-Indole Compounds on Toxoplasma gondii Tachyzoite Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy.Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 - 2010).Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs.Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents.Carbon-carbon double-bond reductases in nature.Recent Advances in the C-H-Functionalization of the Distal Positions in Pyridines and Quinolines.Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015).Crystallization and preliminary X-ray analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae Purification, crystallization and preliminary X-ray diffraction analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus mutans strain UA159 AG205, a novel agent directed against FabK of Streptococcus pneumoniae.Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity.Rational questing for potential novel inhibitors of FabK from Streptococcus pneumoniae by combining FMO calculation, CoMFA 3D-QSAR modeling and virtual screening.Borane-catalyzed metal-free hydrogenation of 2,7-disubstituted 1,8-naphthyridines.

P2860

Q27643926-E546EB37-538A-4B90-846A-35DA0F4BA7A5 Q27647201-9F60F3D4-4B83-4461-9B37-0049CAD20BDE Q27649956-4490E0EF-584A-4E12-8A90-42385A8106D2 Q27651378-D2EEDAE4-55B9-462F-A211-5FD64A9770B4 Q27653711-583760D6-8BA4-4EA1-8533-2B65545CB567 Q27664019-6ABAFAF1-0F04-4549-B85C-DAAEF6F0BF8A Q27675305-F21FB8B4-438E-4219-9292-BB7450C77EBC Q27679331-50351FA6-6044-4AA9-905B-146191797CA3 Q27683440-F1E8F42F-5368-4538-8080-1073C0D9C30C Q28475676-CBA83E7D-6CD8-4D32-B7D8-5942E942F8BD Q29031113-F9B3A785-3A79-4A86-9E34-DBEF9A19F4D8 Q30396236-74ED8DA3-247D-4D15-BDE1-FF27B586BB94 Q33579443-66C5C6DC-9462-4469-8913-18993F27D251 Q34078440-A122A64B-7C27-486D-B61A-7B31AEE25DD2 Q35143373-D1155B6E-BF1F-4A90-901D-5FE3ADE68345 Q35216999-0362BDAF-1F4F-4167-8124-04761833A9C1 Q35542526-78EFBCD8-C63A-4F32-B8CE-C666D473F73B Q35865145-E401FDAB-722A-4A69-A6D5-3DCFB745A763 Q35908735-69642BDE-AF9C-41D9-9154-EB67F2578252 Q36464020-1FA75286-67D9-4AAC-BFBA-D1284730D83B Q36558861-9EE3C335-413B-4257-AF9F-CDE7E9A97DE7 Q36785081-B90E6D8B-27F0-4CD0-89A0-1CF9698769FF Q37283682-9B58F491-4D6A-4DD8-9A54-DE163FC851A6 Q37383936-58E44399-8714-435E-A7D5-5DA027776A0C Q37544698-F480CB77-D1D2-4733-B6AD-CF9C03239AB3 Q37886187-5DB46DCC-8155-4A92-BAA7-2EA3114C7478 Q37979307-1644694C-37B6-463E-A93B-DD99C6F4DD66 Q38019608-DE063A8C-2841-435B-B0DB-064078F35CAE Q38124842-F7A6FE83-2112-4F32-BF32-91ADBFE6223E Q38205904-DF70E67A-F0A2-44C3-B243-D433A5D2B60A Q38660527-4B75F333-6132-4516-A39C-D45BE20238CB Q38765020-B9F4AED9-A20C-4829-A23A-80B99D2B0F31 Q38892242-DF08D391-AE0D-4267-82C0-2C40C515F0F8 Q41870694-9F184345-955C-4803-9897-4C3DEC27C16F Q42000094-650539D5-DBB7-4B18-BF68-96B284ABD3DC Q42112414-3ED0DA2A-F238-45B7-B56E-A47F256B0432 Q42237853-31E80EAC-F3AC-4C24-81EE-E49ADD915165 Q47811083-A74B192E-CBE0-4504-9C0A-36D6F335CDF2 Q51658617-EC40DD20-CEB4-44CC-9A77-DC21488625D0 Q53075796-46ED8212-113F-49C2-8891-AEFF60AB85A9

P2860

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

http://www.wikidata.org/entity/Q27640998

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

@ast

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

@en

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

@nl

type

label

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

@ast

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

@en

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

@nl

prefLabel

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

@ast

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

@en

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

@nl

P1433

Q27640998-53921310-5DDE-4D3F-BD74-37B11D561EE4

P1476

Q27640998-342A3427-9B46-49AE-888A-B82910882B31

P2093

Q27640998-080EFAC2-9A23-4A19-B1D9-3E51E7901D71

Q27640998-1158C698-AE8E-41A0-9FDB-BAA100DA92C1

Q27640998-136E7C7C-615E-423C-BDED-E29C617E07E4

Q27640998-1B7C8CFA-2C64-48D5-B461-0C909C71394B

Q27640998-2E6C08FB-930B-4F68-A771-7892E8971172

Q27640998-4219545B-AB5A-45A8-BD18-44151F1D64A0

Q27640998-4646704A-A96C-4380-8109-BEB885DCF2A8

Q27640998-67499450-1D78-4C1D-B3C0-3E92EEB5E14B

Q27640998-6F89FE25-5E8E-43B4-8154-01A562816285

Q27640998-70E811B4-ADB9-468E-8D52-D046DBB7CEA5

P304

Q27640998-D9A42C35-6D8A-4A15-A193-02A6361AE472

P31

Q27640998-9EC3563C-F991-43C0-9B57-2D1A074F8B5F

P3181

Q27640998-1801AF55-EDA0-440C-9826-F9E3B0B903C0

P356

Q27640998-86F7C72A-F091-4BFE-A3B3-285DBE95EB1A

P407

Q27640998-04847E2A-C450-4621-A2FF-67A9F9202E4B

P433

Q27640998-1132A103-F34C-40B7-A766-207FD31EF66E

P478

Q27640998-DD35117E-C42C-4F3D-9804-A19D426DF043

P577

Q27640998-545F47A9-0419-432D-AF54-6EBDFD3AEE8E

P698

Q27640998-F31BD0AA-9A0B-452E-BE99-BF5008169EFF

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

@en

P2093

Brian J Polizzi

http://www.w3.org/2001/XMLSchema#string

Cheryl A Janson

http://www.w3.org/2001/XMLSchema#string

Dalia R Jakas

http://www.w3.org/2001/XMLSchema#string

David J Payne

http://www.w3.org/2001/XMLSchema#string

Irene N Uzinskas

http://www.w3.org/2001/XMLSchema#string

Kenneth A Newlander

http://www.w3.org/2001/XMLSchema#string

Mark A Seefeld

http://www.w3.org/2001/XMLSchema#string

Martha S Head

http://www.w3.org/2001/XMLSchema#string

Nicola G Wallis

http://www.w3.org/2001/XMLSchema#string

Patricia A Elkins

http://www.w3.org/2001/XMLSchema#string

P304

1627-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2391686

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM0204035

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12699381

http://www.w3.org/2001/XMLSchema#string